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ABSTRACT
DECREASED KIDNEY MITOCHONDRIAL CONTENT AND PGC-1α FOLLOWING
REPEATED LOW-DOSE CISPLATIN-INDUCED KIDNEY INJURY
Andrew Joseph Orwick
May 4, 2021
Cisplatin is highly effective and one of the most commonly used chemotherapeutic
agents in the treatment of a number of different solid organ tumors. Unfortunately, the
dose-limiting nephrotoxicity occurs in up to 30% of patients, which requires alterations to
treatment regimens that are often less effective. The kidney’s function is to provide fluid
homeostasis, and this is an energy-intensive process. Proper renal function is
dependent on functional mitochondria. PGC-1α regulates mitochondrial number,
respiratory capacity, and mitochondrial proteins in proximal tubule cells. We delivered
low-dose cisplatin to mice via intraperitoneal injections once a week for 4 weeks. The
mice were then euthanized, and the kidneys were immediately extracted and frozen. Our
data show that repeated dosing of cisplatin results in reduced renal function, increased
fibrosis, reduced mitochondrial content, and reduced PGC-1α in kidney cortices. We
hypothesize that increasing PGC-1α will protect against cisplatin-induced kidney injury.
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INTRODUCTION
KIDNEY PHYSIOLOGY
The kidney has numerous functions, and is involved in homeostasis, vitamin D
metabolism [1], gluconeogenesis [2], and endocrine functions both locally and
systemically [3-5]. The information discussed below is primarily focused on kidney’s role
in maintaining fluid homeostasis. The kidney manages fluid composition by regulating
the reabsorption and secretion of water, glucose, NaCl, NaHCO3, and amino acids. The
kidneys account for less than 1% of body weight but receive 20-25% of cardiac output
[6, 7]. Additionally, the kidneys consume 7-10% of the total oxygen uptake to produce
enough ATP to carry out the energy-intensive process of reabsorption [6, 8]. The
kidneys have one of the highest resting metabolic per gram of tissue in healthy adults
[9]. The high metabolic rate of the kidneys is mirrored by mitochondrial density and
oxygen consumption per gram of tissue which is the second-highest in the body,
preceded only by the heart [10-12]. The partial pressure of oxygen in the kidney varies
greatly between regions. Blood enters into the kidney through the cortex, and only 10%
of the blood vessels branch off to supply the medulla [8]. Different regions of the
nephron in the cortex have varying partial pressure of oxygen ranging from 90mmHg
down to 20mmHg [8, 13, 14]. The heterogeneity of the oxygen supply in the kidney
makes various regions highly susceptible to hypoxia-induced damage and cell death.
The corticomedullary junction is highly sensitive to hypoxia because it has minimal
perfusion/oxygen supply despite being a highly energy-consuming segment.
The smallest functional unit of the kidney is the nephron, whose ultimate function
is waste excretion through the concentration of filtrate into urine. Nephrons are
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composed of three major sections with distinct roles; (1) the glomerulus that filters the
blood, (2) the tubule that primarily reabsorbs vital nutrients and secretes solutes, and (3)
the collecting duct that carries urine to the calyx, then renal pelvis, and finally exits the
kidneys via the ureters [15]. There are over 26 different cell types in human adult
kidneys to carry out the wide range of functions needed for proper renal function [16].
Glomerular filtration is the first step in urine production and is a passive process
powered by hydrostatic pressure from the heart via glomerular capillaries. The
glomerular filtration rate is the volume of fluid that is filtered per minute. The kidneys filter
between 180-200 liters of blood daily, while the average human only has between 3-5
liters of circulating blood and only produces approximately 1.5 liters of urine [15, 17]. The
tubule has four different segments, each with distinct absorptive properties for
maintaining plasma osmolarity [15]. The renal proximal tubule epithelial cells (RPTEC)
are responsible for 70% of the reabsorption and are highly enriched in mitochondria to
perform this energy-intensive process [18]. RPTECs produce the majority of the required
adenosine triphosphate (ATP) from β-oxidation of fatty acids in the mitochondrial matrix
[19]. This process requires high oxygen levels and makes RPTECs highly susceptible to
hypoxia, IRI, and vasculature damage. The majority of the energy produced in RPTECs
is used for active transport by the Na+/K+ ATPase pump, which generates ion gradients
across the cell membrane for reabsorption of different nutrients against concentration
gradients. Over 90% of the energy production in the kidney occurs through oxidative
phosphorylation, and any disruption to oxygen delivery or mitochondrial function can
increase the risk of acute kidney injury (AKI) [8]. Elevated levels of glycolysis and
increased mitochondrial dysfunction have been identified as hallmarks of various AKI
models [20-22].
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ACUTE KIDNEY INJURY
AKI is defined by a rapid loss is kidney function occurring in a period of hours to
days after insult. A decline in kidney function is characterized by decreased glomerular
filtration rate (GFR), decreased urine production, and increased waste product retention
[23]. The loss in kidney function is measured clinically by an increase in serum creatinine
(SCr) and blood urea nitrogen (BUN) [24]. Hospital admission is a risk factor for
developing AKI, with incidences of 15% for adults and 25% for children after admission
[25, 26]. The incidence rate of AKI for patients admitted into the intensive care unit (ICU)
is above 50% [27]. Multiple studies have shown the development of AKI is also
associated with an increased risk of progressing to chronic kidney disease (CKD) [26,
28-32]. Additionally, the risk of mortality is increased 5 to 6-fold higher in patients with
AKI when compared to patients without AKI [33, 34].
The incidence and prevalence of AKI are difficult to track due to the different
clinical markers used to diagnose and the wide range of disease classifications [35]. In
2004 the Acute Dialysis Quality Initiative proposed the Risk/Injury/ Failure/Loss/ESRD
(RIFLE) classification for AKI [36]. Follow by the Acute Kidney Injury Network (AKIN)
classifications in 2007 [37]. Then in 2012, Kidney Disease: Improving Global Outcomes
(KDIGO) group published guidelines combining the RIFLE and AKIN definitions [38].
These guidelines were developed to provide measurable criteria to universally define the
stages of kidney injury using serum creatinine and urine output. The excretion of waste
products from the blood is a vital function of the kidneys, and a decline in GFR can be
measured by an increase in waste products in the blood. Serum creatinine and blood
urea nitrogen are two waste products that, when elevated, are used to estimate a
decline in GFR. The KDIGO group’s parameters define AKI as an absolute increase in
SCr ≧ 0.3 mg/dL within 48 hours or an increase in SCr ≧ 1.5 times within 7 days, and a
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decrease in urine out of 0.5 ml/kg/hour for 6 hours [38]. The most recent estimate of the
global incidence of AKI is almost 40 cases per 1,000 people [26].
BIOMARKERS OF AKI
The clinical markers of AKI (decreased urine output, elevated SCr, and BUN) are
neither sensitive nor specific for AKI [26]. Additionally, changes in SCr do not correlate
with the severity of kidney damage nor point to the cause of the kidney damage [39, 40].
Changes in serum creatinine are delayed 24-72 hours after the renal injury has
occurred, and its levels are affected by age, race, sex, body weight, metabolism, and
protein intake [35]. BUN has similar limitations to SCr and only elevates after the renal
injury has occurred [41]. New biomarkers that are more specific and sensitive for kidney
damage have been sought after. Two of the newer biomarkers are neutrophil gelatinaseassociated lipocalin (NGAL) and kidney injury molecule 1 (Kim-1).
Neutrophil gelatinase-associated lipocalin (NGAL), 25-kDa polypeptide of the
lipocalin superfamily, was initially identified in human neutrophil gelatinase [42]. NGAL
was first discovered as a biomarker after it was elevated in multiple animal models of
AKI [43-45]. NGAL is a rapid response protein to tissue injury, and while elevated during
AKI events, NGAL is also elevated during acute and chronic inflammatory conditions
[46]. NGAL is released by activated neutrophils during bacterial infections and systemic
inflammation, making its use as a biomarker of AKI more complex [47]. NGAL can be
assayed from blood or urine, but urinary NGAL appears to carry higher specificity for AKI
[48]. NGAL is approved in Canada and Europe for diagnosing AKI [49, 50].
Kim-1 is a transmembrane cell surface receptor on epithelial and
lymphoid/myeloid cells. Kim-1 is a scavenger receptor that removes oxidized LDL
particles and interacts with phosphatidylserine to allow apoptotic cells to undergo
phagocytosis. Under normal conditions, Kim-1 expression in proximal tubule cells is
minimal, but after ischemic or nephrotoxic insult, expression of Kim-1 is significantly
4

upregulated in proximal tubule cells [51, 52]. Kim-1 elevation occurs within 1-3 hours of
kidney injury, making it a very early signal of damage [48]. Additionally, urinary excretion
of Kim-1 has been approved by the FDA and EMA for preclinical assessment of
nephrotoxicity [46, 48].
The heterogeneity of the kidney in cell type, function, tissue oxygenation, and
metabolism further complicates our ability to develop protective measures from AKI [8].
The pathophysiology of AKI is a complex process that is still not completely understood.
The major obstacle is that AKI is a complex process of heterogenous conditions that all
result in loss of kidney function as the endpoint.

ETIOLOGY OF AKI
The kidney encompasses multiple biologic functions, heterogenous tissue
oxygenation, and metabolism, various roles in fluid homeostasis along the nephron
resulting in over 26 cell types. The process of AKI varies according to the primary insult.
The wide range of insults, including nephrotoxic agents, ischemia, dehydration, or
sepsis, damage different regions of the kidney, but all end with reductions in kidney
function. The complexity of the kidney makes the classification of AKI difficult. AKI can
be categorized in multiple ways: the clinical setting, reversibility or response to therapy,
the general mechanism of injury, primary affected anatomical compartment, dominant
underlying pathophysiology, or traditional categories [8]. The traditional categories of AKI
are Prerenal, Intrinsic Renal, and Postrenal [41, 53].
Prerenal AKI is defined as decreased renal perfusion resulting in lower GFR.
Prerenal AKI is the most common cause, with over 70% of the cases attributed to
prerenal causes [53]. The most common cause of prerenal AKI is from loss of fluid
volume. The loss of fluid volume can be from excessive vomiting or diarrhea or overuses
of diuretic drugs. Other causes of prerenal AKI include decreased perfusion from heart
5

failure, systemic vasodilation from sepsis, and changes to intrarenal vasoconstriction via
different medications (NSAIDs, ACE-I, ARBs, Antirejection agents) [53].
Intrinsic AKI is defined by disruption to the internal processes of the kidney.
Intrinsic AKI is further divided up into categories of the primary affected anatomical
compartment. These classifications are divided into glomerular damage, tubular
damage, interstitial damage, and vascular damage [41]. Acute tubular necrosis is the
most common cause of intrinsic AKI in hospitalized patients [41, 53]. The tubular
damage is usually caused by ischemia or nephrotoxic agents. The tubule cells are highly
energetic, where the majority of their energy is produced through oxidative
phosphorylation, making them highly sensitive to prolonged reduction in oxygen delivery.
Different exogenous chemicals, including many commonly used drugs (aminoglycosides,
amphotericin B, cisplatin, radiocontrast media), damage tubule cells resulting in tubule
apoptosis and necrosis.
Acute tubular necrosis-induced AKI involves several pathophysiological
processes, including endothelial damage, vascular impairment, tubular cell death, and
inflammatory/immune response [54]. This process has been divided into four phases,
initiation, extension, maintenance, and recovery [41].
The initiation phase is characterized by functional damage to the tubule cells
from ischemia or nephrotoxic agents and subsequent decreases in renal blood flow,
further decreasing the oxygen levels and ATP production. These damaged cells
epithelial and endothelial cells release cytokines and chemokines, which initiate the
inflammatory cascade. The tubule epithelial cells responsible for most of the kidney's
reabsorption function begin to undergo morphological changes and lose their brush
border membranes. Loss of brush border membranes reduces their surface area and
absorptive capacity. Additionally, the apoptosis or necrosis process begins, and the
dead cells slough off, leading to tubular obstruction [41].
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The extension phase is defined as the persistent hypoxia and inflammatory
response from that initial ischemic or nephrotoxic agent. The heterogeneity of tissue
oxygenation in the kidney makes certain areas more susceptible than others during this
phase [8]. In the cortex, where oxygen levels have returned to near-normal levels, the
tubule cells have started to recover and undergo repair. The corticomedullary junction
(CMJ) and outer medullary region have lower perfusion levels, and the hypoxia leads to
cell injury and ongoing apoptosis/necrosis. As cell death occurs in the CMJ and outer
medulla, the GFR continues to fall. Additionally, the production and release of cytokines
and chemokines continue in these regions during this phase and stimulate the
inflammatory cascade [41].
The maintenance phase characterizes the beginning of repair, increased cell
migration, apoptosis, and proliferation as cells attempted to maintain tubule integrity.
GFR decline halts during this phase as tubule cells begin to dedifferentiate and migrate
towards the damaged area and begin to reestablish tissue structure. Additionally, tissue
perfusion returns to baseline during this phase [41].
Recovery is the final phase of acute tubular necrosis, and as tubule epithelial
cells reestablish their polarity and structure, cellular and organ function returns to
normal. Proinflammatory and profibrotic cells must be cleared for a full recovery. The
ability of the kidney to fully recover from injury is dependent on many factors. Repeated
insults maybe inhibit the repair process and result in chronic impairment [41].
Unlike prerenal injury, in acute tubular necrosis, removing the nephrotoxic agent
or reperfusion of the kidney does not result in immediate recovery. The loss of tubular
cells requires time to replenish and may require renal replacement therapy depending on
the severity [41, 53].
Glomerular damage AKI is caused by acute inflammation of the blood vessel and
glomeruli resulting in loss of renal function. Glomerulonephritis is commonly caused by
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systemic illness, including but not limited to systemic lupus erythematosus, arthritis, viral
infection, and pulmonary-renal syndromes [41, 53].
Damage to the interstitial tissue of the kidney can also result in AKI. The type of
AKI is most commonly caused by allergic reactions to medications or from an infection.
The acute interstitial nephritis generally resolves once the offending agent is removed
[41].
The kidney accounts for less than 1% of total body weight but receives over 20%
of cardiac output [6, 7]. The highly vascularized kidneys are very susceptible to vascular
damage-induced AKI. Damage to the intrarenal blood vessels results in decreased
perfusion and lower GFR. Common causes include arterial catheterization,
hypercoagulation disorders, and vascular surgery [41, 53].
Postrenal causes of AKI are a result of obstruction to urine flow. Prostate
hyperplasia is a common cause of postrenal AKI in older men. Identification and removal
of the obstructing object generally result in a return to baseline [41, 53].
The current markers of AKI are only able to diagnosis after the injury has
occurred and renal function has already declined. There are currently no FDA-approved
agents to prevent or treat AKI. A better understanding of the disease process is needed
to develop potential treatments. It was previously thought that if renal function recovered
(as determined by the return of SCr and BUN to baseline levels) after an AKI incident,
there would be no long-term consequences [55]. Several recent studies have indicated
that patients who develop AKI are up to 10 times more likely to develop chronic kidney
disease (CKD) [28-32]. Even patients that do not develop clinical AKI are at risk for longterm declines in renal function [56, 57]. In this study, the need for dialysis following an
AKI event resulted in an increased risk of developing CKD and mortality [28].
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CHRONIC KIDNEY DISEASE
CKD is defined as the presence of albuminuria, a marker for kidney damage or
decrease in GFR, a marker for kidney function for a duration of greater than 3 months
[55, 58]. Again, because of the complexity of the kidney, CKD is a heterogeneous
disorder affecting the structure and function of the kidney. CKD affects over 20 million
Americans, and over 500,000 have end-stage renal disease (ESRD) [59]. CKD generally
coincides with interstitial fibrosis, glomerulosclerosis, and chronic inflammation [55]. The
most common causes of CKD are diabetes and hypertension [59]. AKI, however, is
becoming more recognized as a potential cause of CKD, even after recovery from initial
nephrotoxic insult [55]. Additionally, more studies have shown that multiple nephrotoxic
events leading to AKI also increase the likelihood of developing CKD [28, 60].
The most common cause of AKI is acute tubular necrosis (see above). After an
AKI event, the kidney utilizes a wound healing process to recover from the insult.
However, the repair process can astray if subsequent insults occur during this time
resulting in maladaptive repair. Maladaptive repair during an AKI event can lead to renal
fibrosis and CKD [55].

MALADAPTIVE REPAIR
Maladaptive repair is defined by incomplete recovery following an AKI event
leading to abnormal kidney structure and function. Increased age and increased number
of repeated nephrotoxic events increase the likelihood of maladaptive repair and
development of CKD. Maladaptive repair is characterized by renal fibrosis, vascular
rarefaction, tubular necrosis/apoptosis, glomerulosclerosis, and infiltrating inflammatory
cells within the kidney [55]. In the maintenance phase of AKI, tubule cells begin to
dedifferentiate and repopulate lost epithelium. Under normal healing conditions, these
cells enter the cell cycle and proliferate to maintain tissue structure [61]. In the
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maladaptive repair process, these cells undergo cell cycle arrest and become
senescent. These senescent cells can adopt a secretory phenotype which is associated
with the release of connective tissue growth factors (CTGF) and transforming growth
factor-beta (TGF-β). CTGF and TGF-β have been associated with chronic inflammation,
collagen deposition, and vascular rarefaction [55].
These secretory senescent cells affect other epithelial cells, pericytes, and the
immune system. Particularly these cytokines increase the production of activated
myofibroblasts [54]. These activated myofibroblasts are considered the primary source
of collagen deposition and fibrotic matrix, which are hallmarks of the maladaptive repair
process [55]. Activated myofibroblasts are essential to the normal healing process where
they deposit extra cellular matrix (ECM), which acts as a scaffold to maintain tissue
structure integrity in damaged tissue. Under maladaptive conditions, the myofibroblasts
are overstimulated, leading to excessive deposition of ECM and renal fibrosis. Renal
fibrosis is defined as excessive deposition and accumulation of extra cellular matrix
(ECM). The accumulation of ECM in renal tissue starts to disrupt normal tissue structure,
impair function, and lead to CKD [62, 63]. In the normal healing process, extra ECM is
degraded, and profibrogenic myofibroblasts are removed. However, repeated
nephrotoxic events or chronic injury can lead to inadequate removal of ECM, resulting in
long-term organ fibrosis [63].
The injured tubule cells also secrete proinflammatory cytokines and chemokines,
leading to the activation of toll-like receptors (TLR). TLRs are a class of cell-surface
proteins that are responsible for activating the innate immune response. Tubule
epithelial cells express TLR, and during AKI events, these receptors are activated,
resulting in the production of tumor necrosis factor-alpha (TNF-α), monocyte
chemoattractant protein 1 (MCP-1), and interleukin 6 (IL-6). Increased cytokine
production leads to immune cell recruitment to the damaged kidney [54]. These immune
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cells are part of the normal healing process and help remove necrotic cells and debris.
Chronic production of these cytokines can lead to overactivation of the immune cells and
maladaptive repair [55].
Repeated nephrotoxic insults impair the normal healing process in the kidney
and can result in maladaptive repair. The maladaptive repair process contributes to the
loss of kidney function as normal tissue structure is not restored in the kidney following
injury. Chronic inflammation and excessive fibrosis are characteristics of the maladaptive
repair process.

CISPLATIN
cis-Diamminedichloroplatinum (II) (cisplatin) is an inorganic water-soluble planar
molecule consisting of only 11 atoms. The molecular structure is a single central
platinum atom surrounded by two chloride and two ammonium atoms in the cis position
(Figure 1A). Cisplatin was first synthesized in 1845 by an Italian chemist, Michael
Peyrone, but the structure was unknown [64]. Nearly 50 years later, in 1893, Alfred
Werner published his transformative paper where he put forward his co-ordination theory
of complex compounds and revealed the chemical structure of cisplatin; he would go on
to receive a Noble Prize in Chemistry for this work in 1913 [65, 66]. Platinum molecules
were thought to have no biological activity until the accidental discovery of cisplatin’s
cytotoxicity by a biophysicist at Michigan State University, Barnett Rosenberg, in 1965
[64, 67]. Dr. Rosenberg's laboratory was investigating the effects of electricity on
bacterial cell growth, and they were using platinum electrodes to deliver the current to
culture media. They discovered the addition of electrical current stopped the cell division
of the bacterial cells. It would take another two years for the laboratory to discover that
electricity was causing the release of platinum molecules responsible for the inhibition of
bacterial cell growth [68]. The Rosenberg laboratory would go on to demonstrate the
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ability of cisplatin to inhibit tumor growth of sarcoma 180 and leukemia L1210 cells, and
next showed the ability of cisplatin to reduce tumor size in a rat sarcoma model [69]. By
1972 the National Cancer Institute began clinical trials using cisplatin for advanced
testicular cancer, and in 1978 cisplatin was FDA approved for testicular, ovarian, and
bladder cancer [67]. Cisplatin was the first inorganic heavy metal used for cancer
chemotherapy and changed how inorganic molecules were viewed [70]. Testicular
cancer outcomes were drastically impacted by the addition of cisplatin to the treatment
regimens. Prior to the use of cisplatin, metastatic testicular cancer had a 90% mortality
rate at 1 year; after the addition of cisplatin, 80% of patients were cured of metastatic
testicular cancer [71].
Cisplatin is now a generic drug, which makes tracking the current usage of
cisplatin difficult. There are currently 215 active treatment trials on ClinicalTrials.gov
database in the United States to highlight cisplatin's continued relevance in clinical
practice. Cisplatin’s mechanism of action involves the formation of DNA, RNA, and
protein adducts, which in turn inhibits DNA synthesis and replication of rapidly dividing
cells [72, 73]. The effectiveness of cisplatin is impaired by its dose-limiting side effect,
nephrotoxicity.
Thirty percent of patients who receive cisplatin develop acute kidney injury (AKI)
[74]. AKI is a life-threatening condition, and the onset of AKI from cisplatin prevents
effective treatment that often requires a change in therapy or dosage reduction. Although
newly developed cisplatin derivatives such as carboplatin and oxaliplatin have reduced
nephrotoxicity, they are much less effective in treating many forms of cancer [75].
Cisplatin would be a much more effective cancer treatment if this toxicity could be
prevented; however, there are currently no therapies approved to prevent or treat AKI.
Understanding how cisplatin induces nephrotoxicity and AKI is crucial to our ability to
develop preventative measures.
12

Figure 1. Cisplatin Chemical Structure and Mechanism of Action.
(A) Chemical structure of cisplatin. (B) Mechanism of action for cisplatin. Created with
BioRender.com
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CISPLATIN’S MECHANISMS OF NEPHROTOXICITY
Cisplatin’s nephrotoxicity correlates with the patient’s dose, frequency, and
cumulative exposure [76]. The kidney receives between 20-25% of the cardiac output
while only accounting for less than 1% of the body weight. Renal cells are exposed to
high levels of cisplatin [6]. Cisplatin in the blood is uncharged and is cleared by the
kidney via glomerular filtration and tubular secretion [77]. Cisplatin, once inside the cell,
becomes charged and accumulates in renal epithelial cells, leading to cisplatin
concentrations higher in the kidney than in the blood [74]. Additionally, cisplatin is
transported intracellularly via copper transporter (Ctr1) and the organic cation transporter
(OCT2), both of which are highly expressed basolaterally on proximal tubule cells,
increasing their susceptibility to cisplatin toxicity [78]. Downregulating Ctr1 in kidney cells
in vitro protected cisplatin toxicity by reducing uptake into the cell [79]. Additionally, the
coadministration of OCT2 substrate reduced cisplatin uptake and toxicity in vitro [80, 81].
The role of OCT2 transport in cisplatin renal toxicity was further confirmed by in vivo
work showing the knockout of OCT2 protected mice from cisplatin nephrotoxicity [82,
83]. Cisplatin-induced nephrotoxicity involves multiple mechanism including proximal
tubule cell damage, increased oxidative stress, inflammatory response, and vascular
injury [74, 78, 84].
The classical mechanism of cisplatin toxicity is through its interaction with DNA
[72, 85, 86]. Once administered, cisplatin enters the bloodstream, where relatively high
concentrations (100mM) of chloride limit the replacement of cisplatin’s two chloride
ligands [86, 87]. However, once inside the cell, the chloride concentrations are much
lower (4-20 mM); this allows cisplatin to be hydrolyzed with the chloride ligand being
replaced by a water molecule (Figure 1B) [86, 87]. The newly formed hydrolyzed
cisplatin is a reactive positively charged electrophile that reacts with nucleophilic sites
forming adducts on DNA, RNA, and protein [85, 86]. Cisplatin binds to DNA is capable of
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forming monoadducts, DNA-protein cross-links, interstrand cross-links, or the most
common intrastrand cross-link adducts [88]. These DNA adducts inhibit the cell's ability
to synthesize DNA resulting in cell cycle arrest of rapidly dividing cells [72, 73]. The antitumor effects of cisplatin were thought to occur through this mechanism, and this was
supported by the finding that cells with defective DNA repair processes were more
sensitive to cisplatin-induced cell death. The idea of nuclear DNA (nDNA) being the
primary target of cisplatin-induced damage and cell death has been contested. In vitro
work has shown that only a small percentage of cellular platinum is bound to nDNA, and
sensitivity to cisplatin cell death poorly correlates with the extent of nDNA platination
[89]. Additionally, work with Chinese hamster ovary (CHO) cells showed that cisplatin
adducts formed at a higher rate on the mitochondrial DNA (mtDNA) compared to the
nuclear DNA (nDNA) [90]. This idea was further supported by in vitro work showing
enucleated cells were sensitive to cisplatin-induced apoptosis independent of nDNA
damage. Other DNA damaging agents were not able to induce this same response,
indicating that cisplatin had unique cytosolic targets [91].
The idea that mitochondria, mitochondrial proteins, and mtDNA are the primary
targets of cisplatin-induced toxicity has been supported by multiple lines of evidence
[92]. Additionally, once intracellular cisplatin becomes a positively charged species,
which preferentially accumulates in the negatively charged mitochondria (Figure 1B) [74,
93]. The density of mitochondria and the mitochondrial membrane potential have been
shown to correlate with increased sensitivity to cisplatin [94, 95]. Another in vitro
experiment treated cells with ethidium bromide to deplete mtDNA, which produced cells
highly resistant to cisplatin toxicity [94]. Mitochondrial DNA is likely more susceptible to
cisplatin-induced DNA damage than nDNA by mitochondria’s lack of effective DNA
repair mechanisms [88, 96, 97]. All of this points to mtDNA as an important factor in the
toxicity of cisplatin.
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Renal proximal tubule epithelial cells (RPTECs) are highly enriched in
mitochondria [18]; express both Crt1 and OCT2 making them very sensitive to cisplatin
toxicity. RPTECs produce the majority of their energy from β-oxidation of fatty acids in
the mitochondrial matrix [19]; cisplatin has been shown to disrupt mitochondrial
energetics and fatty acid oxidation in RPTECs [98-100]. Defective fatty acid oxidation
has been associated with a decline in renal function and the development of renal
fibrosis [101-103]. Agonists of PPAR-α reduce cisplatin nephrotoxicity in vivo [99, 100].
Additionally, damage or loss of mtDNA from cisplatin leads to a loss in mitochondrial
protein levels and a disruption of the mito-nuclear protein ratio leads to reduced
respiratory capacity and malfunctioning RPTECs [104, 105]. Cisplatin also induces cell
death in RPTECs via multiple mechanisms including the extrinsic pathway activated
through death receptors, the intrinsic mitochondrial pathway, and the endoplasmic
reticulum stress pathway [74]. Damage to the RPTECs and their mitochondria leading to
decline in renal function are of particular relevance to this work.
Cisplatin-induced inflammation is another mechanism of nephrotoxicity that has
been studied in cisplatin-induced kidney injury. Cisplatin treatment is associated with
increased expression of many different proinflammatory cytokines and chemokines,
including interleukin 1 beta (IL-1β), IL-6, MCP-1, and TNF-α [78, 84]. Injured RPTECs
release endogenous intracellular molecules known as damage associated molecular
patterns (DAMPs). DAMPs activate Toll-like receptors (TLR), which induce the
expression of inflammatory genes to help repair damaged tissue. The activation of TLR
by DAMPS can result in a positive feedback loop where high levels of tissue damage
result in pro-inflammatory response leading to more tissue damage and chronic
inflammation [106]. Cisplatin-induced inflammation is thought to occur through the
activation of TLR4, leading to the production of chemokines and cytokines, including
TNF-α. Zhang et. al. went on to confirm this by using TLR4 knockout mice that were
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resistant to cisplatin-induced kidney injury and inflammation when compared to wild type
[107]. Other groups have looked specifically at the role of TNF-α in cisplatin-induced
kidney injury. Ramesh and Reeves used TNF-α knockout mouse and a pharmacological
inhibitor of TNF-α; both models provided protection against cisplatin-induced kidney
injury [108]. These experiments also provided data to show inhibition of TNF-α signaling
reduced the production of other key pro-inflammatory mediators. Additionally, Maekawa
et. al. demonstrated how cisplatin induces mitochondrial damage and leakage of mtDNA
into the cytosol. Cytosolic mtDNA activates the cGAS-STING pathway leading to
inflammation which contributes to the development of cisplatin-induced kidney injury
[109], again highlighting the importance of mitochondria in cisplatin-induced kidney
injury.
Cisplatin also damages vascular endothelial cells, which leads to
vasoconstriction and reduced renal blood flow. The reduced renal blood causes a drop
in GFR and creates a more hypoxic environment. The hypoxic conditions following
cisplatin further contribute to tubule cell death and inflammation. The mechanism of
cisplatin’s nephrotoxicity involves tubule cell death, inflammation, and vascular damage;
these pathways are interconnected and show the complexity of cisplatin-induced kidney
injury [84].
The nephrotoxicity of cisplatin has been a problem since it was first introduced
into the clinic. Multiple strategies have been developed to prevent the toxicity. The
adjunct treatment with hydration regimens and the use of diuretics such as mannitol
have been tried with mixed results [110]. Additionally, reduction in dose and extension in
the duration of administration time have been adopted. Unfortunately, there are no
preventative measures approved for cisplatin-induced AKI. The current clinical
guidelines recommend pre-hydration with normal saline and avoiding the use of diuretics
for patient receiving cisplatin therapy [111].
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MODELS OF CISPLATIN INJURY
Thirty percent of patients who receive cisplatin develop acute kidney injury (AKI)
[74]. These patients present with increased BUN and SCr levels, and a rapid decline in
renal function. Traditionally, the accepted standard model of cisplatin-induced kidney
injury has been to use a single high dose (10-30 mg/kg) of cisplatin. This model results
in high levels of tubular necrosis, rapid decline in renal function, and is fatal to mice
within 3-4 days cisplatin [112, 113]. The single high dose model of cisplatin has allowed
researchers to elucidate the mechanisms involved in the patients that develop AKI in the
clinic; however, this model does not allow for long-term studies [113, 114].
In the past, it was assumed that if renal function recovered (as determined by the
return of SCr and BUN to baseline levels) after an AKI incident, there would be no longterm consequences [55]. However, several recent studies indicate that patients who
develop AKI are 10 times or more likely to develop chronic kidney disease (CKD) [2832]. Even patients that do not develop clinical AKI are at risk for long-term declines in
renal function [56, 57]. For the other 70% of patients who have subclinical kidney
damage following cisplatin, little is known about their risk of developing CKD.
In the clinic, patients are typically treated with periodic low doses of cisplatin over
weeks to months, not a single high dose. The Siskind laboratory and others have
recently developed repeated low dose cisplatin (RLDC) models that more closely mimic
the dose regimen of cisplatin in the clinic and enables the study of long-term impacts on
the kidney [112, 113, 115-121]. In the RLDC model, mice receive 7-9 mg/kg cisplatin
once a week for four weeks. The mice treated with the RLDC regimen can survive 6
months following treatment. Published data from our laboratory indicate that the RLDC
model causes a low level of repeated injury [115-120]. These data indicate that repeated
low levels of cisplatin injury induce fibrosis which progresses to CKD and that the cellular
processes induced in the kidney by the RLDC model differ greatly from that when a
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single high dose of cisplatin is administered [115-120]. The mild injury caused by RLDC
that does not meet the clinical criteria for AKI can progress to CKD [115].
The RLDC model can be broken up into two phases, the injury and progression
phases. The injury phase consists of the four weeks of cisplatin treatment and is
characterized by a mild decline in kidney function, ER stress, increased markers of
kidney damage (Kim-1, NGAL), inflammation, and development of fibrosis. The
progression phase is defined by the removal of the nephrotoxic agent and markers of
AKI (Kim-1, NGAL) return to baseline; however, there is persistent inflammation,
increased fibrosis, and development of CKD [115-120]. Additionally, following the injury
phase, mice show mild increases in BUN; however, at the end of the progression phase
(6 months post-treatment), mice have a progressive increase in BUN levels compared to
vehicle-treated mice and the injury phase counterparts. This suggests that mice have
progression and permanent loss of kidney function following the RLDC regimen even
without elevated clinical markers of AKI during the injury phase [115]. The cellular
biology involved in each phase is quite different, and the mechanisms involved in both
phases of this model remain largely unknown [116]. Elucidating these mechanisms is
necessary for identifying novel therapeutic targets.

MITOCHONDRIA AND PGC-1α
As previously mentioned, the kidneys have the highest mitochondrial density and
oxygen consumption per gram of tissue in the body, preceded only by the heart [10, 11].
The kidney is responsible for maintaining fluid homeostasis and the renal proximal
tubule epithelial cells (RPTECs) are responsible for 70% of the reabsorption; RPTECs
are highly enriched in mitochondria to sustain this highly energy-intensive process [18].
RPTECs produce the majority of the required adenosine triphosphate (ATP) from fatty
acid oxidation (FAO) in the mitochondrial matrix [19]. A number of inherited genetic
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mitochondrial diseases coincide with renal impairment to further illiterate the connections
between mitochondrial function and kidney function [122-126]. Disorders of
mitochondrial function are referred to as mitochondrial cytopathies, and the most
common mitochondrial diseases with kidney involvement cause tubular defects [125,
126]. Fanconi Syndrome is an example of a mitochondrial disease with tubular defects
that results in electrolyte disturbances. RPTECs are highly dependent on mitochondrial
function because of their high-energy demand and because they also lack the capability
to synthesize ATP anaerobically from glycolysis [127].
Mitochondria are intracellular organelles with numerous essential roles, including
production of ATP, co-factors, amino acids, induction of apoptosis, calcium homeostasis,
and regulation of cellular redox state and innate immune signaling [128, 129]. Each
mitochondrion has its own circular genome, and there are multiple copies (100-10,000)
per cell [96, 97]. Mitochondria are dynamic organelles with inner and outer membranes
and constantly change their shape and size through fusion and fission processes, known
as mitochondrial dynamics [130]. The opposing effects of fusion and fission are
interconnected and balanced to maintain the overall normal morphology of mitochondria.
Excessive activation of either process can result in fragmentation (fission) or
hypertubulation (fusion), both if left unchecked, can result in mitochondrial dysfunction
[130]. Mitophagy is a mechanism that uses the autophagy pathway to selectively
degrade damaged mitochondria. During AKI events, damaged mitochondria are cleared
via mitophagy and need to be replaced with new mitochondria. New mitochondria are
created from existing ones by a process called mitochondrial biogenesis. Mitochondrial
biogenesis (MB) involves the production of new mitochondrial mass and replication of
mtDNA. MB and replication of mtDNA occurs independent of the cell cycle unlike
replication of nDNA [96]. MB is a highly regulated process, and its activation is controlled
by a set of transcription factors that link environmental cues to cellular energy status and
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adaptive stress response. The master regulator of MB is a transcriptional coactivator,
peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) [103, 131-133].
PGC-1α was identified in brown adipose tissue as a cold-inducible regulator of
adaptive thermogenesis in 1998 by the Spiegelman laboratory [134]. The name is
derived from the originally identified interaction between the PGC-1α protein and PPARγ
(peroxisome proliferator-activated receptor-γ) protein. The Spiegelman laboratory would
go on to show PGC-1α’s role in mitochondrial biogenesis. They demonstrated that PGC1α activated the transcription factor NRF-1 (Nuclear Respiratory Factor 1), which
subsequently leads to the expression of Tfam (Transcription factor A, mitochondrial) and
other nuclear-encoded mitochondrial proteins [135]. The PGC-1α protein is interesting,
as it does not directly bind to DNA, but it binds to other transcription factors already
bound at their respective response elements. The binding of PGC-1α to the already
bound transcription factors coactivates them to exert their regulatory effect [103, 131133, 136]. PGC-1α is highly expressed in metabolically active tissues such as the heart,
kidneys, liver, skeletal muscle, brain, and brown adipose tissue.
It is now understood that PGC-1α is a master transcriptional regulator of many
pathways, including mitochondrial biogenesis, fatty acid oxidation, lipogenesis,
thermogenesis, and glucose metabolism [103, 131-133]. The expression of PGC-1α can
be induced by a number of different external stimuli, including exercise, fasting/nutrient
deprivation, hypoxia, cAMP activation, and oxidant stress. The three main transcription
factors that regulate PGC-1α expression are myocyte enhancer factor-2 (MEF2),
activating-transcription factor 2 (ATF2), and cAMP response element-binding protein
(CREB). The promotor region for PGC-1α contains binding sites for MEF2, ATF2, and
CREB that increase the expression of PGC-1α. ATF2 and CREB bind to the CREBresponsive element (CRE) site, and MEF2 binds to its own specific site on the PGC-1α
promotor. Additionally, PGC-1α expression can be suppressed by external stimuli,
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including pro-inflammatory and pro-fibrotic mediators. The pro-inflammatory factor, TNFα, activates NF-κB, which leads to epigenetic downregulation of PGC-1α via histone H3
deacetylation [137]. Additionally, activation of Notch signaling and its downstream target
Hes1, a profibrotic transcription factor, can directly bind the PGC-1α promoter region and
inhibit PGC-1α expression [138]. Of particular relevance to the RLDC, TGF-β1
stimulates activation of Smad3, which again leads to decreases PGC-1α levels through
epigenetic downregulation [102]. To further add to the complexity of PGC-1α expression,
Long et. al. have shown that long noncoding RNA (lncRNA) taurine-upregulated gene 1
(Tug1) interacts with PGC-1α. They demonstrated that Tug1 acts as a scaffold and
allows the PGC-1α protein to bind to its own promotor and increase expression [139].
Finally, the activation of TLR by various stimuli leads to activation of the MEK1/2,
ERK1/2 pathway, which then interacts with CREB leading to decreased PGC-1α
expression [140].
PGC-1α is also regulated by post-translational modifications, including
phosphorylation, deacetylation, acetylation, and methylation. These modifications affect
the protein's activity and stability and determine which transcription factor will interact
with PGC-1α. There are several kinases that can phosphorylate PGC-1α at multiple
serine and threonine sites. The most well-characterized of these kinases are p38 MAPK,
AKT, AMPK, S6 kinase, and GSK3β. Phosphorylation by AMPK and p38 MAPK leads to
the activation of PGC-1α, whereas phosphorylation AKT inhibits activity and GSK3β
increases its degradation [103, 131-133]. The half-life of the PGC-1α protein is only 2-3
hours, and the phosphorylation p38 MAPK also helps stabilize the PGC-1α protein,
allowing for a longer activity window [141]. Additionally, SIRT1 activates PGC-1α by the
deacetylation of the lysine residues, and PRMT1 (protein arginine methyltransferase 1)
activates PGC-1α by the methylation of arginine residue [103, 131-133]. All of this
together shows that PGC-1α expression and activity are finely tuned and highly
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responsive to environmental cues relaying the energetic/ metabolic demand of the cell to
changes in gene expression.
Mitochondria have over 1,500 proteins, and these are almost entirely encoded in
the nuclear genome. Mitochondrial DNA only encodes two ribosomal RNAs, 22 transfer
RNAs, and 13 messenger RNAs that are all involved in the formation of supercomplexes of the electron transport chain [96, 97, 142]. Proper mitochondrial function
requires coordination between nuclear-encoded mitochondrial genes and the mtDNA
encoded genes. If the replication or synthesis of mtDNA is inhibited or mtDNA is
damaged, the steady-state levels of the mtDNA proteins can be reduced. The significant
reduction in mtDNA encoded proteins results in a mito-nuclear protein imbalance and
subsequent reduction in cellular respiration [96, 97, 142]. As previously stated, PGC-1α
regulates the expression of NRF-1 (Nuclear Respiratory Factor 1). NRF-1, as the name
indicates, is a transcription factor involved with the transcription of nuclear-encoded
electron transport chain components; β-ATP synthase, cytochrome c, and cytochrome c
oxidase subunits. NRF-1 also triggers the expression of Tfam (Transcription factor A,
mitochondrial). Tfam is a transcription factor that, once expressed, translocates from the
nucleus to the mitochondria. Tfam fully coats mtDNA, organizes the mtDNA structure,
and is essential for mtDNA maintenance [143]. Tfam binds to and activates transcription
at the two major promoters of mtDNA [144]. The importance of Tfam is demonstrated in
the global Tfam knockout mice, which are embryonic lethal [145] and the tubule-specific
deletion of Tfam resulted in the development of renal inflammation and fibrosis by 6
weeks of age [146]. By PGC-1α regulating NRF1/2 and Tfam, it controls the expression
of mitochondrial proteins encoded in both the nuclear and mitochondrial genome.
Increased mitochondrial electron transport chain activity is also associated with
increased production of reactive oxygen species (ROS). Excessive ROS production can
lead to DNA damage and cell death. Because of this, PGC-1α is also involved with
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increasing the expression of enzymes needed for the detoxification of ROS. PGC-1α
induces the antioxidant enzymes superoxide dismutase, catalase, and glutathione
peroxidase [147, 148].

PGC-1α AND KIDNEY INJURY
PGC-1α is highly expressed in the proximal tubule cells [149] and human
biopsies from AKI/CKD patients show reduced levels of PGC-1α when compared to
normal human kidney tissue [102, 150, 151]. Additionally, kidney tissue sections from
patients with diabetic kidney disease had lower expression of PGC-1α and dysregulated
mitochondrial function when compared to healthy controls [151]. Reduced mitochondrial
bioenergetics leads to dysfunctional RPTEC and overall loss of renal function [101].
PGC-1α regulates the cell’s energy metabolism and respiratory capacity. Reduced PGC1α levels lead to reduced mitochondrial bioenergetics and a decline in renal function.
The role of PGC-1α expression has been examined in multiple models of AKI and
fibrosis [137, 150, 152-163]. During AKI, damaged mitochondria are removed from cells
via mitophagy and need to be replaced by the generation of new mitochondria via MB.
PGC-1α is the master regulator of mitochondrial biogenesis and bioenergetics;
increasing PGC-1α expression has provided protection against ischemia-reperfusion
injury (IRI) [150, 161-163], sepsis [158, 159], folic acid [137, 154-157], and single high
dose cisplatin [152, 153, 164] induced AKI. More recently, PGC-1α has been shown to
be a key mediator in renal fibrosis and CKD development [102, 103, 133, 136, 138, 151].
Additionally, the Susztak lab has shown that restoring FAO protects against folic acidinduced kidney fibrosis [102]. In mouse models of global and renal proximal tubulespecific PGC-1α knockout, both PGC-1α null mice were unable to recover from sepsisinduced AKI when compared to wild-type mice [165]. Additionally, in vitro work from the
Schnellmann lab showed that the overexpression of PGC-1α in proximal tubular cells
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produced a significant increase in mitochondria number, respiratory capacity, and
intracellular ATP and improved recovery from oxidative damage. This suggests
increasing PGC-1α levels after an AKI may promote repair and recovery [166].
Our laboratory has demonstrated the RLDC model of cisplatin-induced kidney
injury produces mild kidney injury and development of fibrosis. Blood urea nitrogen
(BUN), neutrophil gelatinase-associated lipocalin (NGAL), and urinary kidney injury
molecule-1 (Kim-1) were used to assess kidney damage. Our studies indicate that
following the injury phase of RLDC in C57BL/6j [121], FVB/n [115-117], and B6;129
strains of mice, there are increases in BUN, NGAL, and Kim-1. The microenvironment
created by RLDC is one that is high in inflammatory (TNF-α, IL-6, NLRP3, NF-κB) and
fibrotic mediators (TGF-β1) [115-120]. Increased levels of inflammatory and fibrotic
mediators such as TNF-α and TGF-β1 reduce the expression of PGC-1α [102, 137,
165]. We hypothesize that repeated insult from the administration of cisplatin damages
the RPTEC mitochondria and reduces PGC-1α expression needed to maintain high
levels of FAO and replace damaged mitochondria leading to a decline in renal function
[101-103]. In this study, we set out to examine how kidney mitochondrial and PGC-1α
expression were affected following the injury phase of RLDC model. We believe PGC-1α
is a unique target for the RLDC model because of its role in both AKI and the
development of renal fibrosis/CKD, mirroring the injury and progression phases.
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MATERIALS AND METHODS
ANIMALS
B6129SF1/J (B6;129) mice were purchased from The Jackson Laboratory. B6;129 mice
are a first filial generation hybrids that are the offspring of a cross between C57BL/6J
females (B6) and 129S1/SvlmJ males (129). Upon arrival, the mice were allowed to
acclimate for 1 week prior to the initiation of the experiment. All mice were maintained on
a 12-hour light/dark cycle and provided food and water ad libitum. All animal procedures
were approved by the Institutional Animal Care and Use Committee and followed the
guidelines of the American Veterinary Medical Association.

CISPLATIN DOSING REGIMEN
Pharmaceutical grade cisplatin (NDC 16729-288-38, 1mg/ml) was purchased via the
University of Louisville Outpatient Hospital Pharmacy. The repeated low dose cisplatin
dosing regimen mice were administered cisplatin or vehicle via intraperitoneal (i.p.)
injection once a week between 8-9 a.m. for four weeks. In the vehicle group, 400 μL
normal saline was administered via i.p. injection. In the cisplatin treatment groups,
7mg/kg or 9mg/kg of cisplatin in normal saline in a total volume of 400 μL was
administered via i.p. injection. All mice were administered 500 μL saline by
subcutaneous injection 2 days after dose 3 and 1 day before dose 4 to prevent weight
loss. All animals were injected with cisplatin at the same time of day as there are
circadian influences on the response of the kidney to cisplatin. Animals were euthanized
72 hours following their final cisplatin injection. Upon euthanasia, blood was collected,
and plasma prepared and frozen at -80°C; urine was collected and frozen at -80°C; and
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kidneys were removed, flash-frozen in liquid nitrogen, and stored at -80°C until use. A
cross-section of one kidney from each mouse was fixed in 10% neutral buffered formalin
for histology.

BLOOD UREA NITROGEN (BUN), SERUM CREATININE (SCR), AND NEUTROPHIL
GELATINASE ASSOCIATED LIPOCALIN (NGAL) DETERMINATION
BUN (AMS Diagnostics, 80146) levels were measured from plasma samples using the
indicated kits following the manufactures’ instructions. ELISAs for NGAL (R&D Systems,
DY1857) were performed on the urine as directed by the manufacturer.

PROTEIN QUANTIFICATION AND WESTERN BLOT ANALYSIS
Kidney tissues were homogenized in cell extraction buffer (Thermo Fisher Scientific)
containing a Complete Protease Inhibitor Cocktail Tablet and Phosphatase Inhibitor
Cocktail Tablets (Roche). Homogenates were centrifuged at 15,000 X g for 10 min at 4°
C. Supernatants were removed and stored at -80°C. Protein concentrations were
determined using Bradford Reagent (Bio-Rad). 40 μg of kidney homogenate protein
were loaded and separated on 4–12% gradient Tris-Glycine-SDS polyacrylamide gels.
Protein was then transferred to PVDF membranes that were blocked in 5% (w/v) dried
milk in tris buffered saline 0.1% Tween 20 (TBST) for 1 hour. Membranes were
incubated with primary antibody overnight at 4°C. The next morning, membranes were
washed 3 times for 5 min each with TBST containing 5% (w/v) dried milk. Membranes
were then incubated for 2 hours at room temperature with secondary antibodies
conjugated with horseradish peroxidase (1:20,000) in TBST containing 1% (w/v) dried
milk. Following 2 washes, 1% (w/v) dried milk and 1 wash in TBST membrane proteins
were detected by chemiluminescence substrate.
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ANTIBODIES
The following antibodies were purchased from Cell Signaling Technology (Beverly, MA):
p44/42 MAP Kinase (Erk1/2) #4695, Phospho-p44/42 MAP Kinase (Erk1/2)
(Thr202/Tyr204) #4370, Transforming growth factor-beta (TGF-β) #3711, Mothers
against decapentaplegic homolog 2/3 (SMAD 2/3) #8685, Phospho-Smad2 (Ser465/467)
#3108, Phospho-Smad3 (Ser423/425) #9520. The following antibodies were purchased
from Abcam (Cambridge, CB2 0AX, UK): Peroxisome proliferative activated receptor,
gamma, coactivator 1 alpha (PGC-1α, abcam, ab54481) and α-Smooth Muscle Actin (αSMA, abcam, ab5694). The remaining antibodies include fibronectin (F3648, SigmaAldrich), and α-tubulin (SC-5286, Santa Cruz Biotechnology).

Rodent Total OXPHOS Antibody Cocktail (abcam, ab110413) contains 5 mouse mAbs,
one each against Complex I subunit NDUFB8 (ab110242), Complex II-30kDa (ab14714),
Complex III-Core protein 2 (ab14745), Complex IV subunit I (ab14705) and Complex V
alpha subunit (ab14748) as an optimized premixed cocktail.

GENE EXPRESSION
RNA was isolated from kidney tissue using E.Z.N.A. Total RNA Kit 1 (OMEGA) per
manufacturer’s protocol. cDNA was synthesized with High-Capacity cDNA Reverse
Transcriptase PCR (Thermo Fisher Scientific) per manufacturer’s instructions. Genespecific cDNA was quantified with real-time qRT-PCR using either predesigned TAQman
assays or self-designed SYBR assays. The following TAQman primers were purchased
from Thermo FisherScientific: tumor necrosis factor alpha (TNF-α, Mm00443258_m1),
chemokine (C-X-C Motif) ligand 1 (CXCL1, Mm04207460_m1), and the housekeeping
gene beta-2-microglobulin (B2M, Mm00437762_m1). The following primers were selfdesigned: kidney injury molecule-1 (Kim-1, Invitrogen, forward:
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AGATCCACACATGTACCAACATCAA, reverse: CAGTGCCATTCCAGTCTGGTTT),
Peroxisome proliferative activated receptor, gamma, coactivator 1 alpha (PGC-1α,
Invitrogen, forward: AACAATGAGCCTGCGAACATATT, reverse:
TAGCAAGTTTGCCTCATTCTCTTC), Nuclear Respiratory Factor 1 (NRF1, Invitrogen,
forward: GGATTCCAGTCTCTGTGGACAAA, reverse: CCCCCGACCTGTGGAATACT),
Transcription factor A, mitochondrial (TFAM, Eurofins, forward:
TTTAAAGCTAAACACCCAGATGCA, reverse: TTCTGGTAGCTCCCTCCACAG), TIMP1, Invitrogen forward: GCAACTCGGACCTGGTCATAA, reverse:
TTAGTCATCTTGATCTTATAACGCTGGTA), NLRP3, Invitrogen, forward:
AAGATGAAGGACCCACAGTGTAACTT, reverse: CAGATTGAAGTAAGGCCGGAATT),
and Col1a1, Invitrogen, forward: CGATGGATTCCCGTTCGAGTA, reverse:
GTGGACATTAGGCGCAGGAA) qRT-PCR was done with either iTaq Universal Probes
Supermix (172-5134, Bio-Rad) or iTaq Universal SYBR Green Supermix (172–5124,
Bio-Rad).
FLOW CYTOMETRY
Whole kidneys were homogenized into single-cell suspensions via mechanical disruption
and enzymatic digestion with Liberase DL Research Grade (05466202001,
Millipore/Sigma). After being passed through a 40-μm filter, cells were treated with ACK
Lysing Buffer (A1042-01, Life Technologies) for 2 min to remove red blood cells. Cells
were then suspended in PBS with 0.5% BSA, 0.01% sodium azide, and 2 mM EDTA.
CD16/32 antibody (101321, BioLegend) was used to page Fc-gamma3 receptors. Cells
were then stained with 10 μg/mL of CD45-PerCP (Cat. No. 103130, BioLegend), Ly6CAPC-Cy7 (Cat. No. 560596, BD Biosciences), F4/80-BV421 (Cat. No. 565411, BD
Biosciences), and 7.5 μg/mL of CD11b-BV650 (Cat. No. 563402, BD Biosciences). After
being stained, cells were permeabilized with the FoxP3/Transcription Factor Staining
Buffer Set (Cat. No. 00-5523-00, Invitrogen). Intracellular staining was done with 10
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μg/mL of CD206-PE. Flow cytometry was done using a BD LSRFortessa flow cytometer,
collecting 1 million events per sample.

MITOCHONDRIAL DNA TO NUCLEAR DNA ASSAY
DNA was isolated from kidney tissue using E.Z.N.A. Tissue DNA Kit 1 (OMEGA) per the
manufacturer’s protocol. DNA was quantified using Nanodrop, and 5 ng/μl solutions
were prepared for each sample. 20ng of DNA was loaded into each well, followed by
quantitative PCR using primers designed for specific amplification of particular mtDNA
encoded and nuclear-encoded fragments. Primers were designed to evaluate the
relative copy number of mtDNA and nDNA. The mitochondrially encoded genes selected
were 16S rRNA and ND1, and the nuclear-encoded gene was Hexokinase 2 (HK2)
along with the adaptation of the protocol according to previously published work [167].
Forward and reverse primers 16S rRNA, Invitrogen, forward:
CCGCAAGGGAAAGATGAAAGAC, reverse: TCGTTTGGTTTCGGGGTTTC, ND1,
Invitrogen, forward: CTAGCAGAAACAAACCGGGC, reverse:
CCGGCTGCGTATTCTACGTT, HK2, Invitrogen, forward:
GCCAGCCTCTCCTGATTTTAGTGT, reverse GGGAACACAAAAGACCTCTTCTGG.
qPCR was done with iTaq Universal SYBR Green Supermix (172–5124, Bio-Rad).

CITRATE SYNTHASE ASSAY
Kidney tissues were homogenized in CHAPS solution (1% CHAPS, 150 mM NaCl, 50
mM Tris, 5 mM ETDA) containing a Complete Protease Inhibitor Cocktail Tablet
(Roche). Homogenates were centrifuged at 15,000 X g for 10 min at 4° C. Supernatants
were removed and stored at -80°C. Protein concentrations were determined using
Bradford Reagent (Bio-Rad). Citrate Synthase Assay Kit (Sigma-Aldrich, #:CS0720) was
used to determine relative amounts of citrate synthase per kidney cortices. Citrate
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synthase is the initial enzyme of the tricarboxylic acid (TCA) cycle. The enzyme
catalyzes the reaction of acetyl CoA with oxaloacetate to form the citrate. This enzyme is
an exclusive marker of the mitochondrial matrix and is used as a proxy for mitochondrial
content. The hydrolysis of the thioester of acetyl CoA results in the formation of CoA with
a thiol group (CoA-SH). The thiol reacts with the DTNB in the reaction mixture to form 5thio-2-nitrobenzoic acid (TNB). This yellow product (TNB) is observed
spectrophotometrically by measuring absorbance at 412 nm. Eight (8) μg of kidney
protein was loaded in triplicate per sample, and a change in absorbance was recorded.
The amount of citrate synthase activity was determined using the manufacturers’
instructions.

HISTOLOGY
Following formalin fixation, kidney tissue was processed and embedded in paraffin.
Kidney sections (5 μm) were stained with hematoxylin and eosin (H&E) and periodic acid
schiff (PAS). The degree of morphologic changes was determined by light microscopy.
The following measures were assessed as an indication of morphologic damage to the
kidney after drug treatment: proximal tubule degradation, loss of brush border, tubular
casts, proximal tubule dilation, proximal tubule necrosis, presence of inflammatory cells,
and interstitial fibrosis.

SIRIUS RED/FAST GREEN STAINING
Kidney sections (5 μm thick) were rehydrated in Histoclear followed by an ethanol
gradient. Slides were then dipped in PBS with 0.1% Tween 20 and incubated for 5
minutes. Slides were washed with distilled water twice for 5 minutes each and then
incubated in 1.2% (w/v) saturated picric acid (#5860-32, Ricca Chemicals) containing
0.1% sirius red/direct red 80 (#365548, Sigma) and 0.1% fast green FCF (#F7258,
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Sigma). Slides were then washed with 5% glacial acetic water until the water ran clear.
Tissue samples were then dehydrated and fixed using Permount (#17986-01, Electron
Microscopy Sciences).

IMMUNOHISTOCHEMISTRY
Kidney sections (5 μm thick) were rehydrated in Histoclear followed by an ethanol
gradient. Antigen retrieval was performed in citric acid buffer (pH 6.0) at 95°C in a
steamer for 30 min. Endogenous peroxidases were inhibited with 3% hydrogen peroxide
and dual endogenous enzyme blocker (Dako) for 10 min, followed by two 5-min PBS
washes. Slides were then blocked with avidin for 10 min followed by a PBS wash and
then biotin for 10 min followed by a wash in PBS (Dako). Slides were further blocked
with 5% normal goat serum in 0.1% TBST for 1 h at room temperature. α-SMA primary
rabbit antibody (Abcam) was added to slides at a concentration of 0.5 μg/ml and allowed
to incubate at 4°C overnight. Slides were rinsed with PBS for 5 min, three times.
Biotinylated goat anti-rabbit IgG antibody (1: 25,000, BA-1000, Vector Laboratories) was
added to each section and incubated for 30 min at room temperature. Slides were rinsed
twice with PBS (5 min each). Vector ABC reagent (PK-7100, Vector Laboratories) was
added to each section and incubated for 30 min at room temperature. Slides were rinsed
two times with PBS followed by the addition of 100 µl of DAB substrate for 5-7 min to
detect horseradish peroxidase (SK-4800, Vector Laboratories). Slides were rinsed in
distilled water for 5 min, counterstained with modified Mayer's hematoxylin (no. 72804,
Thermo Scientific), and then dehydrated in an ethanol gradient to Histoclear followed by
mounting with Permount (SP15, Fisher Scientific). Positive staining for α-SMA indicates
the presence of myofibroblasts.
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STATISTICAL ANALYSIS DATA
Data are expressed as means ± SEM for all experiments. Multiple comparisons of
normally distributed continuous data were analyzed by one-way ANOVA, and group
means were compared using Tukey post-tests. Nonparametric continuous data were
analyzed with a Kruskal-Wallis test followed by a Dunn’s multiple comparison test.
Nominal data from pathology scoring were analyzed by individual Chi-squared tests. The
criterion for statistical differences was p < 0.05 for all comparisons.

33

RESULTS
Repeated low-dose cisplatin (RLDC) induces kidney injury in B6;129 mice.
We selected the B6129SF1/J (B6;129) mouse strain because our lab is developing a
syngeneic lung tumor model to investigate the nephrotoxicity of cisplatin with the comorbidity of cancer. Our lab has observed inter-strain variance [121], and the dose of
cisplatin required to induce kidney and fibrosis often varies. To optimize the dose of
cisplatin for the B6;129 mouse strain, we performed an initial cisplatin dose response
experiment in B6;129 mice. The mice were injected (i.p.) with pharmaceutical grade
cisplatin 7mg/kg, 9 mg/kg, or saline (vehicle) once a week for four weeks (Figure 2B.).
All mice were administered 500 μL saline by subcutaneous injection 2 days after dose 3,
and 1 day before dose 4 to prevent dehydration. Mice were sacrificed 72 hours following
the last dose. Blood urea nitrogen (BUN), neutrophil gelatinase-associated lipocalin
(NGAL), and urinary kidney injury molecule-1 (Kim-1) were used to assess kidney
damage. Following RLDC, we observed an increase in BUN (Figure 3A), NGAL (Figure
3B), and Kim-1 (Figure 3C) levels between vehicle and cisplatin-treated groups. The
weights of the mice were monitored throughout the RLDC regimen as a measure of
overt toxicity. We saw a significant loss of body weight between the vehicle and
cisplatin-treated groups and a significant difference between the 7mg/kg and 9mg/kg
cisplatin groups (Figure 3D). Renal histological changes were assessed on 5 μm thick
H&E and PAS stained sections. The PAS-stained sections show a loss of brush border
in the proximal tubule cells from the cisplatin-treated groups (Figure 4). The H&E stained
sections show evidence of tubular necrosis, proximal tubule cast formation, inflammatory
cells, tubule degeneration, and tubule dilation in the cisplatin groups (Figure 5). These
34

findings suggest that repeated low-dose model of cisplatin increases markers of kidney
damage and decreases renal function. Additionally, the kidney function and injury
markers together with the histological changes suggest a dose-response to cisplatininduced kidney injury with higher levels of loss of function (BUN), weight, kidney injury
(Kim-1 and NGAL), loss of proximal tubule brush border, increased cast formation,
increased tubule degeneration, and increased tubule dilation following the injury phase
of the repeated low-dose model of cisplatin-induced kidney injury in the 9 mg/ Kg dose
group than the 7 mg/ Kg dose group.
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Figure 2. RLDC Experiment Design.
(A) Experiment schematic for RLDC model. (B) Experiment design for the study
conducted, B6;129 mice were injected I.P. with 7-9mg/kg cisplatin or normal saline once
a week for four weeks. Mice were euthanized three days following the last dose.
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Figure 3. RLDC induced kidney injury.
(A) BUN levels from serum and (B) NGAL levels from urine following 4 doses of
cisplatin. (C) Kim-1 mRNA expression from the kidney cortex was measured using qRTPCR. (D) Percent change in body weight was recorded throughout RLDC regimen as a
marker of overt toxicity. Data are expressed as means ± SEM; n=5–10. Statistical
significance was determined by 1-way ANOVA followed by Tukey posttest. *p < 0.05,
***p<0.001, ****p < 0.0001
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Figure 4. PAS Stain
Renal histological changes were assessed with PAS-stained 5 μm thick sections. PAS is
used to identify brush borders of proximal tubule cells. (A) Vehicle Control, (B) 7mg/kg,
(C) 9mg/kg. Representative images of renal histology at 40X magnification.
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Figure 5. H&E Stain
Renal histological changes were assessed with H&E stain on 5 μm thick sections. H&E
stain is used to identify tubular necrosis, proximal tubule cast formation, inflammatory
cells, tubule degeneration, and tubule dilation. (A) Vehicle Control, (B) 7mg/kg, (C)
9mg/kg. Representative images of renal histology at 40X magnification.
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RLDC induces renal fibrosis. Fibrosis was evaluated via multiple approaches,
including histopathology, immunohistochemistry (IHC), western analysis, and real-time
qRT-PCR analysis. Sirius red fast green (SRFG) staining indicated collagen
accumulation (Figure 6.) and α-smooth muscle actin (α-SMA) IHC (Figure 7.). Positive
α-SMA indicates an increased number of myofibroblasts in the kidney following the
RLDC regimen and is an indicator of increased fibrosis. Western analysis indicated
increased protein levels of fibronectin and α-SMA (Figure 8A) between the vehicle and
cisplatin-treated groups. The mRNA expression of markers of fibrosis (TIMP-1, Col1a1)
showed a significant increase in the cisplatin-treated groups (Figure 8B, 8C). These
findings suggest that there is a significant development of fibrosis following the injury
phase of the repeated low-dose model of cisplatin-induced kidney injury.
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Figure 6. SRFG Stain
Renal histological changes were assessed with SRFG stain on 5 μm thick sections.
SRFG stains collagen red and is a marker for interstitial fibrosis. (A) Vehicle Control, (B)
7mg/kg, (C) 9mg/kg. Representative images of renal histology at 20X magnification.
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Figure 7. IHC for α-SMA
Renal histological changes were assessed with IHC for α-SMA on 5 μm thick sections.
α-SMA IHC indicates an increased number of myofibroblasts in the kidney and is a sign
of increased interstitial fibrosis. (A) Vehicle Control, (B) 7mg/kg, (C) 9mg/kg.
Representative images of renal histology at 40X magnification.
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Figure 8. RLDC increases protein and mRNA markers of fibrosis
(A) Western blot for Fibronectin, α-SMA, TGF-β1, and α-Tubulin. mRNA expression via
qRT-PCR of TIMP-1 (B), and Col1a1 (C) normalized to B2M. Data are expressed as
means ± SEM; n=5–10. Statistical significance was determined by 1-way ANOVA
followed by Tukey posttest. *p < 0.05, **p<0.01, ***p<0.001.
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RLDC induces renal inflammation. Inflammation was assessed using real-time qRTPCR and flow cytometry. The mRNA expression of inflammatory markers, TNF-α (Figure
9A), CXCL-1 (Figure 9B), and NLRP3 (Figure 9C) showed a significant increase in the
cisplatin-treated groups. We found a significant increase in the percentage of CD45+
immune cells (Figure 10A) in the kidney of cisplatin-treated mice compared to vehicle
control kidneys. We observed significantly increased populations of F4/80 hi and F4/80
lo macrophages (Figure 10B, 10C). These findings suggest that there is a significant
immune response and infiltration to the kidney following cisplatin-induced renal damage
in the repeated low-dose model.
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Figure 9. RLDC induced kidney inflammation.
(A) qRT-PCR of TNF-α, CXCL-1 (B), and NLRP3 (C) normalized to B2M. Data are
expressed as means ± SEM; n=5–10. Statistical significance was determined by 1-way
ANOVA followed by Tukey posttest. ***<0.001, ****p < 0.0001.

49

C D 4 5 + % S in g le C e lls

A.

T o t a l Im m u n e C e lls
A N O V A p = 0 .0 0 1 9

25

***
**

20
15
10
5
0

V e h i c le

7 m g /k g

9 m g /k g

C is p la tin

F 4 /8 0 h i % o f S in g le C e lls

B.

R e s id e n t M a c r o p h a g e
A N O V A p = 0 .0 0 0 4
**

2 .0
***

1 .5
1 .0
0 .5
0 .0

V e h i c le

7 m g /k g

9 m g /k g

C is p la tin

F 4 /8 0 lo % o f S in g le C e lls

C.

In f ilt r a t in g M a r c o p h a g e s
A N O V A p < 0 .0 0 0 1

2 .0

*
****

1 .5

*

1 .0
0 .5
0 .0

V e h i c le

7 m g /k g

9 m g /k g

C is p la tin

Figure 10. Immune Cell Infiltration
Flow cytometric analysis of renal immune cells. Whole kidneys were homogenized and
~1 million cells were stained. One million events were collected from each sample.
Analysis identified CD45+ immune cells (A), CD11b+ F4/80 hi resident macrophages (B),
CD11b+ F4/80 lo infiltrating macrophages (C). Populations are expressed as a
percentage of the number of single cells counted. Data are expressed as means ± SEM;
n=5–10. Statistical significance was determined by 1-way ANOVA followed by Tukey
posttest. *p < 0.05, **p<0.01 ***<0.001, ****p < 0.0001.
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RLDC reduces total kidney mitochondrial content. As previously mentioned, the high
metabolic activity and density of mitochondria in the kidney led us to investigate the
effects of the RLDC model on kidney mitochondrial content. We performed three
different assays to evaluate mitochondrial content in the kidneys following RLDC. First,
we quantified the ratio of mtDNA to nDNA as described [167]. RLDC resulted in a
significant reduction in the mtDNA/nDNA ratio (Figure 11A), indicating a loss of mtDNA
and suggesting a loss of mitochondrial mass. We also evaluated citrate synthase activity
on kidney cortex homogenate. Data indicate a significant decrease in citrate synthase
activity following RLDC treatment (Figure 11B). Finally, we performed western analysis
of the electron transport chain (ETC) complex proteins. Data indicate a decrease in
complexes 1-5 of ETC subunits (Figure 11C). These results suggest that following the
injury phase of the RLDC model, there is a significant reduction in kidney mitochondria.
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Figure 11. RLDC reduces kidney mitochondrial content.
(A) qPCR on nuclear-encoded Hexokinase 2 (HK2) and mitochondrial encoded 16S
were used to calculate the ratio between mtDNA to nDNA as a marker for mitochondrial
content, normalized to vehicle-treated kidneys. (B) Citrate Synthase Activity measured
using Sigma-Aldrich kit (CS0720). (C) Western blot for electron transport chain (ETC)
subunits of super-complex proteins: Complex 1 (NDUFB8), Complex 2 (SDHB),
Complex 3 (UQCRC2 ), Complex 4 (MTCO1), and Complex 5 (ATP5a). Data are
expressed as means ± SEM; n=5–10. Statistical significance was determined by 1-way
ANOVA followed by Tukey posttest. *p< 0.05, **p<0.01, and ****p < 0.0001.
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RLDC reduces the expression of PGC-1α and its downstream targets. The previous
results lead me to investigate possible causes of the reduced mitochondrial content. The
RLDC models causes a significant reduction in PGC-1α protein evaluated by western
analysis (Figure 12A) and mRNA expression evaluated by real-time qRT-PCR (Figure
12B). Data indicate decreased levels of PGC-1α at the mRNA and protein level. I next
evaluated genes whose expression is regulated by PGC-1α. Nuclear respiratory factor 1
(Nrf1) expression is increased by PGC-1α, and it triggers the activation of multiple
mitochondrial genes encoded in the nucleus [131]. Nrf1 expression is significantly
reduced following RLDC (Figure 13A). One gene whose expression is regulated by Nrf1
is Tfam (transcription factor A, mitochondrial), and its expression is significantly reduced
in the RLDC model (Figure 13B). Tfam binds to and activates transcription at the two
major promoters of mitochondrial DNA (mtDNA) [144]. Tfam is responsible for organizing
and maintaining mtDNA structure [143], and loss of Tfam in a mouse model resulted in
the development of renal inflammation and fibrosis by 6 weeks of age [146]. Reduced
Tfam results may be related to reduced mtDNA levels as shown in Figure 11A. mtDNA
has a less efficient repair process compared to nuclear DNA (nDNA), making mtDNA
highly susceptible to cisplatin-induced damage [168, 169].
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Figure 12. RLDC reduces the expression of PGC-1α.
(A) Western blot for PGC-1α and α-Tubulin. (B) qRT-PCR of PGC-1α normalized to
B2M. Data are expressed as means ± SEM; n=5–10. Statistical significance was
determined by 1-way ANOVA followed by Tukey posttest. ****p < 0.0001.
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Figure 13. RLDC reduces the expression of PGC-1α’s downstream targets.
qRT-PCR of NRF1 (A), Tfam (B) normalized to B2M. Data are expressed as means ±
SEM; n=5–10. Statistical significance was determined by 1-way ANOVA followed by
Tukey posttest. ****p < 0.0001.
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RLDC increases the expression of inhibitory pathways that regulate PGC-1α
expression.
The previous results lead me to investigate possible causes of the reduced PGC-1α
protein and mRNA expression. As previously stated, PGC-1α expression and activity are
finely tuned and highly responsive to changes in the microenvironment. PGC-1α is
negatively regulated by pro-inflammatory and profibrotic cytokines. We looked at
profibrotic factor TGF-β1 and phosphorylation of downstream target Smad 2 and Smad 3
by western analysis (Figure 14A). We looked at pro-inflammatory cytokine TNF-α mRNA
expression by real-time qRT-PCR (Figure 14B). As mentioned previously, activation of
TLR4 has been seen in cisplatin models of injury. We looked at phosphorylation of
ERK1/2, which is a downstream target of TLR4 by western analysis (Figure 14A). Data
indicate increased levels of multiple inhibitors of PGC-1α expression and activity
following the injury phase of the RLDC model.
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Figure 14. RLDC increases the
expression of inhibitory pathways that regulate PGC-1α expression
(A) Western blot for TGF-β1, p-Smad2, p-Smad3, total Smad 2/3, p-ERK1/2, total
ERK1/2, and α-Tubulin. (B) qRT-PCR of TNF-α normalized to B2M. Data are expressed
as means ± SEM; n=5–10. Statistical significance was determined by 1-way ANOVA
followed by Tukey posttest. ****p < 0.0001
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DISCUSSION
Cisplatin is a highly effective first-line chemotherapeutic agent, but its usage is
limited by its nephrotoxicity. Cisplatin is commonly used to treat many solid-organ
cancers, including head, neck, testicular, breast, ovary, and lung [74]. The effectiveness
of cisplatin can be seen in the remission rates of testicular cancer that went from 5% to
80% when cisplatin was approved for its treatment [114]. Thirty percent of cancer
patients treated with cisplatin develop AKI [74]. AKI is a life-threatening condition defined
as a rapid decrease in renal function and is diagnosed clinically by an increase in serum
creatinine (SCr) and blood urea nitrogen (BUN) [24]. The onset of AKI from cisplatin
prevents effective treatment and often requires a change in therapy or dosage reduction.
Although newly developed cisplatin derivatives such as carboplatin and oxaliplatin have
reduced nephrotoxicity, they are much less effective in treating many forms of cancer
[75]. Cisplatin would be a much more effective cancer treatment if this toxicity could be
prevented; however, there are currently no therapies approved to prevent or treat AKI.
Despite the high rate of AKI development, 10-20% of all cancer patients are
prescribed cisplatin as part of their treatment regimen [67]. In the past, it was assumed
that if renal function recovered (as determined by the return of SCr and BUN to baseline
levels) after an AKI incident, there would be no long-term consequences [55]. However,
several recent studies indicate that patients who develop AKI 10 times or more likely to
develop chronic kidney disease (CKD) [28-32]. Even patients that do not develop clinical
AKI are at risk for long-term declines in renal function [56, 57]. As we improve diagnosis
and treatment of cancer, the number of cancer survivors is increasing. In 2016, there
were 15.5 million cancer survivors in the U.S., and that number is estimated to increase
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to 20.3 million by 2026 [170]. AKI and CKD incidences have also been increasing [29,
171, 172]. Thus, cisplatin-induced kidney injury (CDDP-KI) is an important unmet
medical need and places a large burden on patient quality of life as well as our
healthcare system.
There is a great need to develop therapeutic strategies to protect from CDDP-KI
in order to increase cisplatin's therapeutic potential and decrease the rate of CKD
development in cancer survivors. All clinical trials on nephroprotective agents have
failed, and we believe this is in part due to a lack of clinically relevant animal models.
Traditionally, the accepted standard model of CDDP-KI has been to use a single
high dose of cisplatin. This model results in high levels of tubular necrosis, rapid decline
in renal function, and is fatal to mice within 3-4 days cisplatin [112, 113]. In the clinic,
patients are typically treated with periodic low doses of cisplatin over weeks to months,
not a single high dose. The Siskind laboratory and others have recently developed
repeated low dose cisplatin (RLDC) models that more closely mimic the dose regimen of
cisplatin in the clinic and enables the study of long-term impacts on the kidney [112, 113,
115-121]. The mechanism of RLDC leading to CKD is poorly understood and appears to
be vastly different from the acute model. Unpublished data from our lab has shown
agents that are protective in the acute model provide no benefit in the chronic RLDC
model. Other models of CKD and fibrosis have shed light on possible mechanisms, but it
is still unclear how RLDC leads to a decline in renal function and fibrosis. This model
allows us to study the pathology of CDDP-KI in a way that more closely mirrors the
pathology of patients receiving CDDP in the clinic.
The results from RLDC model indicates that repeated low levels of cisplatin injury
induce fibrosis which progresses to CKD and that the cellular processes induced in the
kidney by the RLDC model differ greatly from that when a single high dose of cisplatin is
administered [115-120]. The mild injury caused by RLDC that does not meet the clinical
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criteria for AKI can progress to CKD [115] and better represent the 70% of patients that
receive cisplatin without clinical markers of AKI. Furthermore, the RLDC model can be
broken up into two phases, the injury and progression phases. The injury phase, which
consists of the four weeks of cisplatin treatment and is characterized by a mild decline in
kidney function, ER stress, increased markers of kidney damage (Kim-1, NGAL),
inflammation, and development of fibrosis. The progression phase is defined by removal
of the nephrotoxic agent and markers of AKI (Kim-1, NGAL) return to baseline; however,
there is persistent inflammation, increased fibrosis, and development of CKD [115-120].
The cellular biology involved in each phase is quite different, and the mechanisms
involved in both phases of this model remain largely unknown [116]. Elucidating these
mechanisms is necessary for identifying novel therapeutic targets.
To better understand the mechanism involved in the RLDC, this study evaluated
the effects of repeated low-dose cisplatin (RLDC) on kidney mitochondria content and
kidney PGC-1α expression. The RLDC model results in kidney injury and the
development of fibrosis, along with reduced mitochondrial content and PGC-1α
expression. Reduced PGC-1α is seen in human renal biopsies from AKI/CKD patients
when compared to normal human kidney tissue [102, 150, 151]. Increasing PGC-1α
expression has provided protection in multiple models of AKI, including IRI [150, 161163], sepsis [158, 159], folic acid [137, 154-157], and single high dose cisplatin [152,
153, 164]. Additionally, increasing PGC-1α in other cell types besides RPTEC may not
be protective, as shown by Li and colleagues, where podocyte-specific inducible
overexpression of PGC-1α actually accelerated progression toward end-stage renal
disease by inducing collapsing focal and segmental glomerulosclerosis [173].
Cisplatin has been shown to preferentially accumulate in mitochondria [74, 93],
and sensitivity to cisplatin correlates with mitochondria density and membrane potential
[94, 95]. Furthermore, mtDNA is more susceptible to cisplatin-induced DNA damage
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than nDNA because of the mitochondria’s lack of effective DNA repair mechanisms [88,
96, 97]. Damage or loss of mtDNA from cisplatin leads to a loss in mitochondrial protein
levels, and a disruption of the mito-nuclear protein ratio leads to reduced respiratory
capacity and malfunctioning RPTECs [104, 105]. Additionally, multiple studies have
demonstrated that damaged mtDNA is degraded to counteract ineffective mtDNA repair
processes and prevent the accumulation of damaged mtDNA [174]. Degradation of
damaged mtDNA leads to the release of fragmented mtDNA in the cytosol and activation
of the innate immune response [96, 174]. Activation of the innate immune response by
cytosolic mtDNA has been shown to be directly involved with the development of AKI
and renal fibrosis [109, 146] and sheds light on a possible mechanism of the RLDC
induced model of kidney injury (Figure 15).
The RPTEC are responsible for 70% of the reabsorption, are highly enriched in
mitochondria [18], and rely on FAO to sustain adequate ATP levels [19]. We hypothesize
that repeated insults from cisplatin preferentially targets kidney mitochondria resulting in
mild RPTEC death, clearance of damaged mitochondria, initiation of the inflammatory
cascade, which all coalesce to a decline in renal function. The microenvironment created
by RLDC is proinflammatory (TNF-α) and profibrotic (TGF-β), both of which suppress the
activity and expression of PGC-1α. The reduced PGC-1α and subsequent reduced
mitochondrial content, functionality, and intracellular ATP results in dysfunctional
RPTEC. Inherited genetic mitochondrial diseases coincide with renal impairment [122126], and the most common of these genetic diseases lead to tubular defects [125, 126],
demonstrating the importance of RPTEC in proper renal function. The repeated insult of
cisplatin impairs RPTEC's ability to recover which, results in a maladaptive repair
process leading to fibrosis and development of CKD. We believe increasing PGC-1α
expression following administration of cisplatin will restore lost FAO activity,
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mitochondria content, increase antioxidant enzymes and intracellular ATP to RPTEC,
leading to increased kidney repair processes and kidney function.
Future studies are needed to examine the relationship between PGC-1α
expression and the development of fibrosis/CKD in both phases of the RLDC model. We
believe that increasing PGC-1α expression during the injury and progression phases of
RLDC will protect against kidney injury and prevent progression to CKD, respectively.
Experiments utilizing pharmacological inhibitors and inducers of PGC-1α, as well as
transgenic mice overexpressing PGC-1α or with PGC-1α deletion, are required to
determine the role of PGC-1α in the different stages and whether it is a potential
therapeutic target. The results from these proposed experiments will help answer if
changing PGC-1α expression during the injury phase of RLDC will provide any
protection. This information will be very useful in developing future therapeutic agents for
clinic practice.
The progression phase of the RLDC has its own distinct cellular biology, and the
role of PGC-1α needs to be investigated separately. PGC-1α has been shown to be a
key mediator in renal fibrosis and CKD development [102, 103, 133, 136, 138, 151]. We
propose carrying out the same proximal tubule-specific overexpression and knockout
studies but starting the intervention only after the four doses of cisplatin have been
administered. For the 70% of patients that receive cisplatin with no clinical markers of
AKI, it is currently not known if later presentation of kidney damage can be reversed.
Studying the progression phase of the RLDC will help to undercover the mechanisms
involved with this process. Additionally, the proposed studies will allow us to intervene
after subclinical damage has occurred and will provide useful information about the
ability to reverse subclinical kidney damage and prevent progression to CKD. This
information will fill key knowledge gaps, providing scientific advances for the field.

62

The mouse models used to study cisplatin-induced AKI are not fully
representative of patients who receive multiple low doses of cisplatin in the clinic. The
current models lack solid organ tumors, and our preliminary unpublished data suggest
the co-morbidity of lung cancer potentiates the nephrotoxicity of cisplatin. We have
developed a subcutaneous transplanted syngeneic lung cancer model to investigate the
interaction between the co-morbidity of cancer and cisplatin nephrotoxicity.
Understanding the role of solid organ tumors in cisplatin-induced nephrotoxicity may
provide mechanistic insights and novel therapeutic targets for the prevention and
effective treatment of cisplatin-induced AKI-CKD. Lastly, any protective measure
developed to limit the nephrotoxicity of cisplatin must also consider its effect on cancer
viability.
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Figure 15. Graphical Abstract of RLDC Model
Created with BioRender.com
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SUMMARY
Cisplatin is a first-line chemotherapeutic for many solid organ cancer types, but
its usages are limited by its nephrotoxicity. Thirty percent of patients who receive
cisplatin develop acute kidney injury (AKI), which increases the risk of chronic kidney
disease (CKD) and mortality. There are currently no treatment options to prevent or treat
cisplatin-induced kidney injury (CDDP-KI).
Cisplatin-induced kidney injury (CDDP-KI) has been extensively investigated in
the past by our lab and many other labs using a single, high-dose model. However,
patients are typically treated with periodic low doses of cisplatin, not a single high dose.
Our lab and others have recently developed a potentially more clinically relevant model
utilizing repeated low-dose cisplatin (RLDC) treatment. In this new model, mice receive 4
weekly doses of low dose cisplatin and are able to survive more than 6-months posttreatment. The RLDC model can be broken up into two phases. The repeated low-level
injury phase, which consists of the four weeks of cisplatin treatment and is characterized
by a mild decline in kidney function, insignificant levels of tubule cell death, inflammation,
and development of fibrosis. After the injury phase, there is a progression phase that is
characterized by persistent inflammation, exacerbated fibrosis, and the development of
CKD. The mechanisms involved in both phases of this model remain largely unknown.
The kidneys have the highest mitochondrial density and oxygen consumption per
gram of tissue in the body, preceded only by the heart. The majority of the reabsorption
performed occurs in the renal proximal tubule epithelial cells (RPTECs). These cells are
highly enriched in mitochondria and rely on fatty acid oxidation (FAO) as their many
energy source. Cisplatin has been shown to disrupt FAO, and defective FAO in RPTEC
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is seen in other models of fibrosis. Our data suggest that the RLDC model causes a
decrease in renal function, mitochondrial content, and PGC-1α. PGC-1α is a master
transcriptional regulator of mitochondrial biogenesis, fatty acid oxidation, lipogenesis,
thermogenesis, and glucose metabolism. Future studies are needed to examine the
relationship between PGC-1α expression and the development of fibrosis/CKD in both
phases of the RLDC model. We believe that increasing PGC-1α expression during the
injury and/ or progression phases of RLDC will protect against kidney injury and prevent
progression to CKD, respectively.
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-Facilitate weekly team meetings, assist with future/current client meetings, determine
contract and bonus. Educate sales team on current and new product lines
Manage daily operations of the pharmacy
Proficiency in Pharmacy Benefit Managers Formularies and coverage
June 2012-August 2014, Compounding Pharmacist
Precision Compounding Pharmacy
Proficiency in Pharmacy Benefit Managers Formularies and coverage
Manage daily operations of the pharmacy
Manage daily operations of the compounding lab
Calculate monthly sales report for pharmacy
PK software advanced user
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May 2009–May 2012, Compounding Tech/Pharmacy Intern
Precision Compounding Pharmacy
Compounding prescriptions
Maintenance and cleaning in compounding lab.

May 2004-August 2005, Clerk
Davis Drug Store, INC
Cashier

Education
June 2012, Doctor of Pharmacy, Sullivan University College of Pharmacy
May 2009, Biology Minor, IUPUI
Educational Conferences
IACP Compounders on Capitol Hill, Washington, D.C., June 2018
PCCA International Seminar, Houston, TX, November 2014
PCCA International Seminar, Houston, TX, October 2013
PCCA Comprehensive Compounding Course, Houston, TX, September 2013
PCCA PK Software Advanced Users Course, Houston, TX, April 2013
PCCA Aseptic Technique Compounding Course, Houston, TX, January 2013
PCCA Marketing-Sales-Business Course, Austin, TX, April 2012
PCCA Sports Medicine/Pain Management Symposium, Colorado Springs, CO, August 2011
PCCA Student Boot Camp, Houston, TX, June 2011
Skills
Leadership
Problem Solver
Time Management
Public Speaking
Teamwork
Adaptability/Flexibility
Interpersonal Skills

Licenses and Certificates
State of Indiana Pharmacist License
References available upon request
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